Publications

Sort publications on year

  • Pharmaco-Economics

    What is the budget impact of a new treatment or new health technology arriving on the market?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII

    Therapie ; 2017;72(1):93-103

  • Pharmaco-Economics

    Quel impact budgétaire pour l’arrivée d’un nouveau traitement ou d’une nouvelle technologie de santé ?

    DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants à la table ronde n(o) 3 de Giens XXXIII.

    Therapie ; 2017;72(1):81-91

  • Pharmaco-Economics

    Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France

    FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.

    BMJ Open ; 2017;7(9):e015571

  • Pharmaco-Economics

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M

    Joint Bone Spine ; 2019;86(1);69-75

  • Pharmaco - Epidemiology

    Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.

    BARBUT F, GALPERINE T, VANHEMS P, LE MONNIER A, DURAND-GASSELIN B, CANIS F, JEANBAT V, DUBURCQ A, ALAMI S, BENSOUSSAN C, FAGNANI F.

    Health Qual Life Outcomes ; 2019;17(1);6

  • Pharmaco-Economics

    Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

    BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.

    J Med Econ ; 2018; 21(12):1213-1220

  • Biometry and database analysis

    Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD ZOUBIR A, LAFUMA A, LÉVY-BACHELOT L, GOURMELEN J, LINET T.

    Eur J Contracept Reprod Health Care ; 2018;23(6):421-426

  • Public Health and Epidemiology

    Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France.

    GOZLAN G, LECARDEUR L, MONFORT AS, DOZ M, ORTIZ I, LARROUMETS P, LAFUMA A.

    Encephale ; 44:496-503.

  • Market Access

    Clinical added value of drugs : An empirical survey of French transparency committee opinions.

    DETOURNAY B, BOREL T, TRANCART M, EMERY C, COUDRAY-OMNES C, LEEM WORKING GROUP ONHEALTH TECHNOLOGY ASSESSMENT OF DRUGS.

    Thérapie ; 2018;S0040-5957(18)30245-2

  • Biometry and database analysis

    Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database

    DALLONGEVILLE J, SACHER F, BOUEE S , EMERY C, BUREAU I, GOURMELEN J, FAUCHIER L.

    Therapie ; 2018;73:449-460

  • Public Health and Epidemiology

    Facteurs associés au maintien dans le poste de travail après un épisode d’absence : résultats de l’étude MAPOST des médecins du travail du groupe La Poste.

    DUBURCQ A, COUROUVE L, HAVETTE P, DAB W & Le Comité Des Médecins Du Travail De La Poste

    Archives des Maladies Professionnelles et de l'Environnement ; 2018,79(6);705-716

  • Pharmaco-Economics

    Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries

    LAURENDEAU C, LAFUMA A, BERDEAUX G

    J Med Economics ; 12(3):230-237

  • Pharmaco - Epidemiology

    Screening to detect permanent childhood hearing impairment in neonates transferred from the newborn nursery

    DAUMAN R, ROUSSEY M, BELOT V, DENOYELLE F, ROMAN S, GAVILAN-CELLIÉ I, RUZZA-SURROCA I, CALMELS MN, LINA-GRANADE G, HOUSSIN E, CHARLEMAGNE A, GARABEDIAN N

    Int J Pediatr Otorhinolaryngol ; 73(3):457-465

  • Public Health and Epidemiology

    Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001

    ROBERT J, ROUDIER C, POUTIGNAT N, FAGOT-CAMPAGNA A, WEILL A, RUDNICHI A, THAMMAVONG N, FONTBONNE A, DETOURNAY B

    Bull Epidemiol Hebd ; 42-43:455-460

  • Pharmaco - Epidemiology

    Prevalence of diagnosed type 2 diabetes mellitus in the French general population : The INSTANT study

    BRINGER J, FONTAINE P, DETOURNAY B, NACHIT-OUINEKH F, BRAMI G, ESCHWEGE E

    Diabetes Metab ; 35(1):25-31